- Alcohol was the most commonly detected substance (25.1 per cent), followed by cannabinoids, (14.1 per cent), benzodiazepines, (13.4 per cent), amphetamine-type substances (10.9 per cent), opioids (3.8 per cent) and cocaine (2.3 per cent).
- 61.8 per cent of those injured on Friday and Saturday nights tested positive for alcohol or other drugs.
- 39.8 per cent of those injured in low falls (falls from standing or a height less than one metre) and 27.6 per cent of those injured in high falls (falls from a height more than one metre) tested positive to alcohol or other drugs. The combined figure was 32.6 per cent.
Alcohol and other drug use more prevalent in non-car injuries: studyMonash University 3 mins read
More from this category
- Environment, Medical Health Aged Care
WA doctors and health professionals call for the government to take urgent action on climate change and end fossil fuel expansion to protect health
On the 1st December, just prior to the COP28 Health Day on the 3rd December, representatives of the medical colleges for general practitioners (GPs), emergency doctors, rural and remote doctors, and surgeons, as well as other doctors and health professionals, gather at 8 am on the steps of Parliament House to call on the WA Government take urgent action on climate change and protect the health of Western Australians. Reiterating calls from medical colleges earlier this year in support of ending fossil fuel expansion and climate action, those gathered today ask the WA government to: End expansion of any new…
- Medical Health Aged Care
ADIA congratulates Senators of the Inquiry into the Provision of and Access to Dental Services in Australia
1 December The Australian Dental Industry Association congratulates the Senators of the Senate Select Committee Inquiry into the Provision of and Access to Dental…
- Medical Health Aged Care, Research Development
Aegros Releases Top-Line Interim Clinical Trial Results of its COVID-19 Hyperimmune
Aegros Releases Top-Line Interim Clinical Trial Results of its COVID-19 Hyperimmune Aegros, an Australian clinical-stage biopharmaceutical company leader in the development and manufacture of plasma derived medicinal products (PDMPs), today announced positive top-line interim results from its CHAT clinical trial. Top-line interim results indicate that Aegros’ COVID-19 hyperimmune provides higher levels of antibodies compared to high-titer convalescent plasma. These results are in line with Aegros’ pre-clinical expectations. CHAT compared Aegros’ COVID-19 hyperimmune to COVID-19 convalescent plasma. The hyperimmune was manufactured using Aegros’ patented Haemafrac® process. A hyperimmune is an intravenous immunoglobulin rich in antibodies that can provide passive immunity for…